-$0.15 EPS Expected for VYNE Therapeutics Inc. (NASDAQ:VYNE) This Quarter

Equities analysts forecast that VYNE Therapeutics Inc. (NASDAQ:VYNEGet Rating) will report earnings of ($0.15) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for VYNE Therapeutics’ earnings. VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth rate of 59.5%. The company is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that VYNE Therapeutics will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.53). For the next year, analysts anticipate that the business will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.73) to ($0.37). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for VYNE Therapeutics.

VYNE Therapeutics (NASDAQ:VYNEGet Rating) last announced its quarterly earnings results on Thursday, March 17th. The company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.05. VYNE Therapeutics had a negative return on equity of 106.54% and a negative net margin of 496.98%.

A number of analysts have recently commented on VYNE shares. Cantor Fitzgerald reissued an “overweight” rating on shares of VYNE Therapeutics in a research note on Friday, March 18th. Zacks Investment Research raised VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 13th.

Shares of VYNE stock opened at $0.49 on Wednesday. The business’s 50-day moving average price is $0.59 and its 200-day moving average price is $0.89. VYNE Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.47. The firm has a market capitalization of $27.72 million, a price-to-earnings ratio of -0.34 and a beta of 0.96.

Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its holdings in VYNE Therapeutics by 175.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 115,698 shares of the company’s stock worth $118,000 after purchasing an additional 73,642 shares in the last quarter. Virtu Financial LLC increased its holdings in VYNE Therapeutics by 61.8% in the fourth quarter. Virtu Financial LLC now owns 175,278 shares of the company’s stock worth $179,000 after purchasing an additional 66,959 shares in the last quarter. Susquehanna International Group LLP increased its holdings in VYNE Therapeutics by 217.1% in the fourth quarter. Susquehanna International Group LLP now owns 45,330 shares of the company’s stock worth $46,000 after purchasing an additional 31,033 shares in the last quarter. Marshall Wace LLP bought a new stake in VYNE Therapeutics in the fourth quarter worth approximately $169,000. Finally, DSC Advisors L.P. increased its holdings in VYNE Therapeutics by 131.9% in the fourth quarter. DSC Advisors L.P. now owns 2,551,000 shares of the company’s stock worth $2,602,000 after purchasing an additional 1,451,000 shares in the last quarter. 26.73% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile (Get Rating)

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.

Featured Articles

Get a free copy of the Zacks research report on VYNE Therapeutics (VYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VYNE Therapeutics (NASDAQ:VYNE)

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.